Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00438815
Other study ID # LEVP2006-1
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 21, 2006
Est. completion date March 31, 2009

Study information

Verified date May 2021
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study objective was to evaluate the safety and efficacy of repeat use of C1INH-nf for the treatment of acute HAE attacks.


Description:

A total of 113 subjects were enrolled in the study. One-hundred-one (101) subjects received C1INH-nf for the treatment of 1 or more HAE attacks and were analyzed for efficacy. The study design also allowed for short-term prophylaxis with C1INH-nf prior to emergency or non-cosmetic surgical or dental procedures, and an additional 12 subjects received C1INH-nf only for this purpose. All 113 subjects were exposed to C1INH-nf and analyzed for safety.


Recruitment information / eligibility

Status Completed
Enrollment 113
Est. completion date March 31, 2009
Est. primary completion date March 31, 2009
Accepts healthy volunteers No
Gender All
Age group 1 Year and older
Eligibility Inclusion Criteria: This study was open to all subjects who: - Completed participation in LEVP2005-1/A (NCT00289211) and were not participating in LEVP2005-1/B (NCT01005888), any time after the 3-day telephone follow-up - Completed participation in LEVP2005-1/B any time after the final prophylactic therapy in Part B - Were enrolled but not randomized in LEVP2005-1/A after Part A was closed - Were excluded from LEVP2005-1 for any of the following reasons: - Pregnancy or lactation - Age less than 6 years - Narcotic addiction - Presence of anti-C1INH autoantibodies - Were not enrolled in LEVP2005-1 after enrollment in LEVP2005-1 was closed, under the following circumstances: - Had a diagnosis of HAE: evidence of a low C4 level plus either a low C1INH antigenic level or a low C1INH functional level, or - Had a known HAE-causing C1INH mutation, or - Had a diagnosis of HAE based on a strong family history of HAE as determined by the principal investigator Exclusion Criteria: - History of allergic reaction to C1INH or other blood products - Participated in any other investigational drug study within the past 30 days - Received blood or a blood product in the past 60 days other than C1INH-nf

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
C1 esterase inhibitor [human] (C1INH-nf)


Locations

Country Name City State
United States Family Allergy and Asthma Center Atlanta Georgia
United States MeritCare Clinical Research Bemidji Minnesota
United States Allergy and Asthma Clinic of Northwest Arkansas Bentonville Arkansas
United States Montefiore Medical Center Bronx New York
United States Allergy & Asthma Centre of Dayton Centerville Ohio
United States AARA Research Center Dallas Texas
United States Welborn Clinic Allergy and Immunology Evansville Indiana
United States MeritCare Clinical Research Fargo North Dakota
United States Allergy and Asthma Center Fort Lauderdale Florida
United States University of Texas Medical Branch Galveston Texas
United States Allergy Partners of the Upstate Greenville South Carolina
United States Penn State University Hershey Pennsylvania
United States Baylor College of Medicine Houston Texas
United States Allergy Asthma and Dermatology Research Center Lake Oswego Oregon
United States Nevada Access to Research and Education Society Las Vegas Nevada
United States UCLA-David Geffen School of Medicine Los Angeles California
United States Winthrop University Hospital Mineola New York
United States Mount Sinai School of Medicine New York New York
United States UMDNJ Asthma and Allergy Research Center Newark New Jersey
United States Orlando Regional Healthcare Orlando Florida
United States Cornerstone Healthcare Parkersburg West Virginia
United States Allergy and Asthma Research Center San Antonio Texas
United States University of California, San Diego San Diego California
United States Allergy and Immunology Associates Scottsdale Arizona
United States Marycliff Allergy Specialists Spokane Washington
United States Grand Traverse Allergy Traverse City Michigan
United States Allergy Clinic of Tulsa Tulsa Oklahoma
United States Allergy and Asthma Clinical Research, Inc Walnut Creek California
United States Institute for Asthma and Allergy Wheaton Maryland
United States University of Massachusetts Medical School Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Shire

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Hereditary Angioedema (HAE) Attacks Treated With C1INH-nf Duration of the study (2.5 years)
Primary Percent of HAE Attacks With Substantial Relief of the Defining Symptom Subjects were to assess their symptoms every 15 minutes up to 4 hours after the initial dose or until substantial relief of the defining symptom was achieved. The conservative analysis defined substantial relief as 3 consecutive assessments of improvement of the defining symptom; any attack that did not have 3 consecutive documented reports of improvement was considered a treatment failure. In the less conservative analysis, attacks also were considered to have responded if clinical improvement of the defining symptom occurred but data were incomplete due to cessation of symptom assessments. Within 4 hours after initial treatment
Secondary Time to Beginning of Substantial Relief of the Defining Symptom Subjects were to assess their symptoms every 15 minutes up to 4 hours after the initial dose or until substantial relief of the defining symptom was achieved. Substantial relief was defined as 3 consecutive assessments of improvement of the defining symptom. Beginning of substantial relief was considered the first of the 3 consecutive assessments. Within 4 hours after initial treatment
Secondary Time to Beginning of Substantial Relief of the Defining Symptom for Subjects Who Received Multiple Treatments For attack number 1, the number of censored observations precluded estimation of the 95% confidence interval (CI) upper bound for median time to event (subjects who did not experience beginning of substantial relief of the defining symptom within 4 hours after initial treatment were included in the analysis as censored observations). Entry of 4.0 hours indicates that data were not estimable (NE); as non-numeric data are not supported by the 95% CI field, entry of the actual result (ie, NE or >4.0) was not possible. Within 4 hours after initial treatment
Secondary Antigenic C1 Inhibitor (C1INH) Serum Levels Change in antigenic C1INH serum levels from pre-infusion to 1 hour after the initial dose of study drug. Pre-infusion to 1 hour post-infusion
Secondary Functional C1INH Serum Levels Percent change in functional C1INH serum levels from pre-infusion to 1 hour after the initial dose of study drug. Functional C1INH serum levels are expressed as a percent of total detectable C1INH (ie, functional C1INH/total detectable C1INH). Pre-infusion to 1 hour post-infusion
Secondary Complement C4 Serum Levels Change in complement C4 serum levels from pre-infusion to 1 hour after the initial dose of study drug. Pre-infusion to 1 hour post-infusion
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06007677 - A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema Phase 2
Completed NCT00997204 - EASSI - Evaluation of the Safety of Self-Administration With Icatibant Phase 3
Completed NCT00748202 - Berinert P Study of Subcutaneous Versus Intravenous Administration Phase 3
Completed NCT01426763 - A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase Phase 2
Terminated NCT04091113 - Hereditary Angioedema Kininogen Assay
Completed NCT00432510 - Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects Phase 1
Completed NCT03712228 - A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) Phase 2
Active, not recruiting NCT05453968 - Berotralstat Treatment in Children With Hereditary Angioedema Phase 3
Recruiting NCT05511922 - PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial Phase 3
Recruiting NCT05505916 - An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) Phase 3
Completed NCT02303626 - 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks Phase 2/Phase 3
Not yet recruiting NCT02159430 - Hereditary AngioEdema, Neurobiology and Psychopathology N/A
Completed NCT01984788 - Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE Phase 2
Completed NCT04888650 - Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema
Completed NCT02448264 - First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers Phase 1
Completed NCT05118958 - Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations Phase 1
Completed NCT06414252 - Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients
Active, not recruiting NCT04739059 - Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks Phase 3
Completed NCT02819102 - An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates Phase 1
Completed NCT01679912 - A Call Center During HAE Attacks (SOS HAE) Phase 4